|Table of Contents|

Anti-angiogenesis therapy with bevacizumab as maintenance treatment in a patient with small cell lung cancer：A case report and literature review

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 03
Page:
411-415
Research Field:
Publishing date:

Info

Title:
Anti-angiogenesis therapy with bevacizumab as maintenance treatment in a patient with small cell lung cancer：A case report and literature review
Author(s):
Xue Peng1; 2; Zhou Lei2; Li Linlu1; Xu Pengpeng1; Wang Ningjun2; Wang Fang2; Zhu Shijie2
1.Beijing University of Chinese Medicine，Beijing 100029，China；2.Department of Oncology，Wangjing Hospital，China Academy of Chinese Medical Sciences，Beijing 100102，China.
Keywords:
extensive stage small cell lung cancer; bevacizumab; survival time
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2019.03.013
Abstract:
Objective：To investigate the effect of bevacizumab on the progression-free survival and overall survival of patients with extensive stage small cell lung cancer.Methods：We reported a case with 5 cycles of chemotherapy combined bevacizumab and 8 cycles of bevacizumab maintained therapy，and review the relevant literature.Results:The patient achieved 10 months progression-free survival.Conclusion：Bevacizumab for the treatment of extensive small cell lung cancer can prolong progression-free survival and prolong survival.

References:

[1]Riaz SP，Luchtenborg M，Coupland VH，et al.Trends in incidence of small cell lung cancer and all lung cancer［J］.Lung Cancer，2012，75(3)：280-284.
[2]Chen W，Zheng R，Baade PD，et al.Cancer statistics in China，2015［J］.Ca A Cancer Journal for Clinicians，2016，66(2)：115.
[3]Kalemkerian GP,Akerley W,Bogner P,et al.Small cell lung cancer［J］.Natl Compr Canc Netw,2013,11:78-98.
[4]Howlader N，Noone AM，Krapcho M，et al.Previous version SEER cancer statistics review，1975-2010［R/OL］.［2013-6-14］.https://seer.cancer.gov/archive/csr/1975__2010/.
[5]Noda K，Nishiwaki Y，Kawahara M，et al.Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer［J］.N Engl J Med，2002，346(2)：85-91.
[6]Hermes A，Bergman B，Bremnes R，et al.Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer：A randomized phase Ⅲ trial［J］.J Clin Oncol，2008，26(26)：4261-4267.
[7]Han D，Wang G，Sun L，et al.Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer：A Meta-analysis［J］.European Journal of Cancer Care，2017，26(264-269)：e12723.
[8]Hanna N，Bunn PJ，Langer C，et al.Randomized phase Ⅲ trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer［J］.J Clin Oncol，2006，24(13)：2038-2043.
[9]Lara PJ，Natale R，Crowley J，et al.Phase Ⅲ trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer：Clinical and pharmacogenomic results from SWOG S0124［J］.J Clin Oncol，2009，27(15)：2530-2535.
[10]Lima JP，Dos SL，Sasse EC，et al.Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer：Systematic review with Meta-analysis［J］.J Thorac Oncol，2010，5(12)：1986-1993.
[11]Schiller JH.Current standards of care in small-cell and non-small-cell lung cancer［J］.Oncology，2001，61(Suppl 1)：3-13.
[12]Zhou H，Zeng C，Wei Y，et al.Duration of chemotherapy for small cell lung cancer：A Meta-analysis［J］.PLoS One，2013，8(8)：e73805.
[13]Ferrara N，Gerber HP，Lecouter J.The biology of VEGF and its receptors［J］.Nat Med，2003，9(6)：669-676.
[14]Lucchi M，Mussi A，Fontanini G，et al.Small cell lung carcinoma（SCLC)：The angiogenic phenomenon［J］.Eur J Cardiothorac Surg，2002，21(6)：1105-1110.
[15]Stefanou D，Batistatou A，Arkoumani E，et al.Expression of vascular endothelial growth factor（VEGF)and association with microvessel density in small-cell and non-small-cell lung carcinomas［J］.Histol Histopathol，2004，19(1)：37-42.
[16]Sandler A，Gray R，Perry MC，et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer［J］.N Engl J Med，2006，355(24)：2542-2550.
[17]Cremolini C，Loupakis F，Antoniotti C，et al.FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer：Updated overall survival and molecular subgroup analyses of the open-label，phase 3 TRIBE study［J］.Lancet Oncol，2015，16(13)：1306-1315.
[18]Ruan G，Ye L，Liu G，et al.The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer：An updated systematic review and Meta-analysis［J］.Onco Targets Ther，2018，11：521-528.
[19]Horn L，Bernardo P，Sandler A，et al.A phase Ⅱ study of paclitaxel+etoposide+cisplatin+concurrent radiation therapy for previously untreated limited stage small cell lung cancer（E2596)：A trial of the Eastern Cooperative Oncology Group［J］.J Thorac Oncol，2009，4(4)：527-533.
[20]Spigel DR，Greco FA，Zubkus JD，et al.Phase Ⅱ trial of irinotecan，carboplatin，and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer［J］.J Thorac Oncol，2009，4(12)：1555-1560.
[21]Spigel DR，Townley PM，Waterhouse DM，et al.Randomized phase Ⅱ study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer：Results from the SALUTE trial［J］.J Clin Oncol，2011，29(16)：2215-2222.
[22]Ready NE，Dudek AZ，Pang HH，et al.Cisplatin，irinotecan，and bevacizumab for untreated extensive-stage small-cell lung cancer：CALGB 30306，a phase Ⅱ study［J］.J Clin Oncol，2011，29(33)：4436-4441.
[23]Pujol JL,Lavole A,Quoix E,et al.Randomized phase Ⅱ-Ⅲ study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer:Results from the IFCT-0802 trialdagger［J］.Ann Oncol,2015,26:908-914.
[24]Tiseo M，Boni L，Ambrosio F，et al.Italian，multicenter，phase Ⅲ，randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer：The GOIRC-AIFA FARM6PMFJM trial［J］.J Clin Oncol，2017，35(12)：1281-1287.

Memo

Memo:
-
Last Update: 2018-12-29